{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:30:27Z","timestamp":1784251827333,"version":"3.55.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0153140","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T19:43:30Z","timestamp":1459971810000},"page":"e0153140","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study"],"prefix":"10.1371","volume":"11","author":[{"given":"Ignacio","family":"Ortea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Roschitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva G.","family":"Tomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Ovalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez-Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Gonz\u00e1lez-Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"IB McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"JS Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis","volume":"70","author":"JD Isaacs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"JS Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1136\/annrheumdis-2013-203297","article-title":"Reply to: forget personalized medicine and focus on abating disease activity","volume":"72","author":"WS Wilke","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/acr.22289","article-title":"Rheumatoid arthritis: a case for personalized health care?","volume":"66","author":"MA Karsdal","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","article-title":"Differences in binding and effector functions between classes of TNF antagonists","volume":"45","author":"T Arora","year":"2009","journal-title":"Cytokine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"D Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"K Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"JD Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis","volume":"43","author":"RJ Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2013.04.004","article-title":"Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies","volume":"81","author":"E Salgado","year":"2014","journal-title":"Joint Bone Spine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e1003394","DOI":"10.1371\/journal.pgen.1003394","article-title":"Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis","volume":"9","author":"J Cui","year":"2013","journal-title":"PLoS Genet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/FPC.0000000000000042","article-title":"Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis","volume":"24","author":"A Montes","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-015-0571-z","article-title":"Rheumatoid arthritis response to treatment across IgG1 allotype\u2014anti-TNF incompatibility: a case-only study","volume":"17","author":"A Montes","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jprot.2012.09.011","article-title":"Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis","volume":"77","author":"I Ortea","year":"2012","journal-title":"J Proteomics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard.2008.093153","article-title":"Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis","volume":"68","author":"C Trocme","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"AM van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00216-012-5918-6","article-title":"An insight into iTRAQ: where do we stand now?","volume":"404","author":"C Mol Cell ProteomicsEvans","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1021\/pr500880b","article-title":"Isobaric labeling-based relative quantification in shotgun proteomics","volume":"13","author":"N Rauniyar","year":"2014","journal-title":"J Proteome Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1074\/mcp.T600050-MCP200","article-title":"The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra","volume":"6","author":"IV Shilov","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nmeth1019","article-title":"Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry","volume":"4","author":"JE Elias","year":"2007","journal-title":"Nat Methods"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/beheco\/ark016","article-title":"The unequal variance t-test is an underused alternative to Student\u2019s t-test and the Mann\u2013Whitney U test","volume":"17","author":"GD Ruxton","year":"2006","journal-title":"Behavioral Ecology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2006.03.011","article-title":"Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism","volume":"372","author":"M Speeckaert","year":"2006","journal-title":"Clin Chim Acta"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"J Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"D Elewaut","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"TR Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref28","first-page":"1","article-title":"Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions: Systematic Review and Meta-analysis","author":"JR Maneiro","year":"2013","journal-title":"JAMA Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"GM Bartelds","year":"2011","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket017","article-title":"The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure","volume":"52","author":"SB Krintel","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","first-page":"429","article-title":"Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70","volume":"6","author":"ME Orme","year":"2012","journal-title":"Biologics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2011-200228","article-title":"A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach","volume":"71","author":"S Schmitz","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"KL Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"JJ Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"C Gabay","year":"2013","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry","volume":"71","author":"JD Greenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"A Frazier-Mironer","year":"2014","journal-title":"Joint Bone Spine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","article-title":"Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients","volume":"71","author":"SM Du Pan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"A Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study","volume":"71","author":"JJ Gomez-Reino","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","article-title":"Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register","volume":"64","author":"MM Soliman","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"P Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"G Dennis Jr.","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Y Sanayama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial","volume":"66","author":"J Sellam","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","article-title":"The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients","volume":"14","author":"HG Raterman","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"ref47","first-page":"5497","article-title":"Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis","volume":"59","author":"ES Berleth","year":"1999","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0153140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:44:49Z","timestamp":1655444689000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0153140"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0153140","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]}}}